Azenta Inc AZTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AZTA is a good fit for your portfolio.
News
-
Azenta Publishes its 2023 Environmental, Social, & Governance (ESG) Report
-
Azenta to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Azenta to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum
-
Azenta Reports First Quarter Results for Fiscal 2024, Ended December 31, 2023
-
Azenta Launches the BioArc™ Ultra, a Breakthrough, Automated Solution for Efficient, Eco-Friendly Ultracold Sample Management
-
Azenta shares jump on Q4 results, buyback plans
Trading Information
- Previous Close Price
- $52.09
- Day Range
- $50.75–51.67
- 52-Week Range
- $36.01–69.16
- Bid/Ask
- $51.48 / $51.50
- Market Cap
- $2.87 Bil
- Volume/Avg
- 346,933 / 462,252
Key Statistics
- Price/Earnings (Normalized)
- 188.56
- Price/Sales
- 4.95
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 15.41%
Company Profile
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3,500
- Website
- https://www.azenta.com
Competitors
Valuation
|
Metric
|
AZTA
|
HPQ
|
6762
|
|---|---|---|---|
Price/Earnings (Normalized) | 188.56 | 8.34 | 29.93 |
Price/Book Value | 1.16 | — | 1.73 |
Price/Sales | 4.95 | 0.53 | 1.34 |
Price/Cash Flow | 97.83 | 6.77 | 9.43 |
Price/Earnings
AZTA
HPQ
6762
Financial Strength
|
Metric
|
AZTA
|
HPQ
|
6762
|
|---|---|---|---|
Quick Ratio | 4.84 | 0.35 | 1.21 |
Current Ratio | 5.87 | 0.71 | 1.67 |
Interest Coverage | — | 7.10 | 3.77 |
Quick Ratio
AZTA
HPQ
6762
Profitability
|
Metric
|
AZTA
|
HPQ
|
6762
|
|---|---|---|---|
Return on Assets (Normalized) | −0.66% | 9.25% | 3.73% |
Return on Equity (Normalized) | −0.75% | — | 7.92% |
Return on Invested Capital (Normalized) | −1.97% | 41.54% | 5.36% |
Return on Assets
AZTA
HPQ
6762
Medical Instruments & Supplies Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Nccbhqxcz | Xmqg | $133.8 Bil | |
BDX
| Becton Dickinson & Co | Fxdhyrhhw | Qnxqvlw | $67.6 Bil | |
ALC
| Alcon Inc | Qfpljlnhh | Hzvjlgg | $39.1 Bil | |
CLPBY
| Coloplast A/S ADR | Wgwzkkkr | Cpx | $29.7 Bil | |
WST
| West Pharmaceutical Services Inc | Qbjhhcsfpl | Zsk | $28.6 Bil | |
RMD
| ResMed Inc | Qnpjfdvqsq | Gdgpz | $27.0 Bil | |
BAX
| Baxter International Inc | Nfzwsrps | Zpnsz | $20.9 Bil | |
COO
| The Cooper Companies Inc | Wfjqfggc | Vrvhnl | $18.2 Bil | |
HOLX
| Hologic Inc | Nmyvwkzzr | Rzchjgf | $17.9 Bil | |
TFX
| Teleflex Inc | Bvnk | Mjt | $9.9 Bil |